What happens to a constitutional right when the court meant to protect it takes four years and 57 hearings to say nothing at all? The Supreme Court just answered that question - one hearing too late for the woman whose case it was.

A Right That Died Waiting For Its Own Case

The Two Failures Stacked on Each Other

This story is really two failures wearing one headline. The first is executive: the Centre declined to issue a government-use licence under the Patents Act because it judged that breast cancer - a disease that kills roughly 90,000 women in India every year - did not meet the threshold of "national urgency." The second is judicial: even after that refusal was challenged, the case meant to test it was listed 57 times over four years without a single conclusive hearing.

The petitioner did not lose her case. She died before anyone got around to deciding it. This is the specific failure mode this story is built around: Article 21 doesn't just require that a right exist on paper - it requires that the mechanism for enforcing it actually functions in the time a human body has left. A right that takes longer to vindicate than a patient has to live is not, in any meaningful sense, a right at all.

Why "Suo Motu" Matters Here The Supreme

Court did not wait for an appeal. It took suo motu cognisance

• acting entirely on its own initiative, after the Kerala High Court's delay came to its notice. This is a judiciary catching its own institutional failure rather than being forced to by petitioner action and it signals something specific: the Court is treating case-management delay in health-related Article 21 matters as a systemic problem worth correcting from the top, not an isolated administrative lapse in one High Court.

The Legal Mechanism Nobody Used

Buried inside this story is a specific legal tool that went unused: Section 100 of the Patents Act, 1970, which lets the Central Government use a patented invention - including manufacturing it domestically at lower cost - for public purposes.

Since 2005, India has invoked compulsory licensing provisions like this only once, for the cancer drug Nexavar in 2012. The Centre's refusal here wasn't a legal impossibility; it was a discretionary call that "national urgency" wasn't met, for a disease killing tens of thousands of women annually.

That discretionary threshold, not the law itself, is what the petition was actually challenging.

What the Supreme Court's Intervention Actually Fixes The

Court didn't rule on Ribociclib's pricing. It ruled that the Kerala High Court must decide the matter expeditiously and - significantly - that once it does, the directions "may be followed on a pan-India basis." This converts what began as one patient's individual grievance into a template for how courts nationally should handle life-saving drug access cases: fast and understood as an Article 21 matter from the outset, not an ordinary civil dispute that can wait its turn on a crowded docket.

The Uncomfortable Symmetry There's a

structural irony worth naming directly: the very institution meant to correct the executive's narrow reading of "national urgency" took longer to act than the patient had left to live. Judicial self-correction here isn't just about getting the eventual answer right - it's an acknowledgment that speed itself is part of what Article 21 demands and that a court can violate a right through delay just as an executive can through denial.